Acuta Capital Partners, LLC Catalyst Biosciences, Inc. Transaction History

Acuta Capital Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.91 - $4.16 $332,150 - $1.52 Million	-365,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.78 - $5.18 $1.21 Million - $1.66 Million	-320,000 Reduced 46.72%	365,000 $1.5 Million
Q2 2021 Aug 16, 2021	SELL	$4.1 - $5.33 $1.04 Million - $1.36 Million	-254,500 Reduced 27.09%	685,000 $2.97 Million
Q1 2021 May 17, 2021	SELL	$4.93 - $7.15 $2.06 Million - $2.99 Million	-418,000 Reduced 30.79%	939,500 $4.74 Million
Q4 2020 Feb 16, 2021	SELL	$4.55 - $7.29 $638,820 - $1.02 Million	-140,400 Reduced 9.37%	1,357,500 $8.57 Million
Q2 2020 Aug 14, 2020	BUY	$3.76 - $8.01 $426,008 - $907,533	113,300 Added 8.18%	1,497,900 $8.79 Million
Q1 2020 May 15, 2020	BUY	$3.5 - $8.51 $4.85 Million - $11.8 Million	1,384,600 New	1,384,600 $6.05 Million
Q3 2018 Nov 07, 2018	SELL	$9.35 - $12.44 $7.76 Million - $10.3 Million	-830,000 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$9.11 - $28.88 $2.96 Million - $9.38 Million	-324,722 Reduced 28.12%	830,000 $9.69 Million
Q1 2018 May 15, 2018	BUY	$14.18 - $35.6 $9.99 Million - $25.1 Million	704,722 Added 156.6%	1,154,722 $29.8 Million
Q4 2017 Feb 14, 2018	BUY	$4.52 - $13.69 $2.03 Million - $6.16 Million	450,000	450,000 $6.14 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.